ERBB2 and breast carcinoma: Another ongoing phase 1b/2 study on zanidatamab in combination with docetaxel, but as the first-line treatment of advanced HER2-positive breast cancer patients, has also shown an encouraging result with a confirmed ORR of 90.5% and a 6-month PFS rate of 95.2% (89).